Fig. 1: SARS-CoV-2 neutralization by sera from BNT162b2 vaccinated individuals.

a, Proportion of individuals with detectable serum neutralization of PV after the first dose of Pfizer BNT162b2 vaccine by age. Cut-off for serum neutralization is an inhibitory dilution at which 50% inhibition of infection is achieved (ID50) of 20. Shading, 95% CI. b, Serum neutralization of PV after dose 1 (blue) and dose 2 (red) by age group (<80 years (n = 79), ≥ 80 years (n = 59)). c, Neutralization curves for serum from two individuals (ID 4 and ID 8) with lower responses after the first dose (blue) and increased neutralization activity after the second dose (red) of BNT162b2 against pseudovirus expressing wild-type spike protein (D614G). Data shown as mean ± s.e.m. of technical replicates. d, f, Neutralization of SARS-CoV-2 VOCs by sera after dose 1 (d) and dose 2 (f) of BNT162b2. d, WT, n = 138; B.1.1.7, n = 135; B.1.351, n = 82; P.1, n = 82. f, WT, n = 64; B.1.1.7, n = 53; B.1.351, n = 32; P.1, n = 32. Data shown as GMT ± s.d. e, g, The proportion of participant vaccine sera with neutralization activity against wild-type and mutant spike proteins after dose 1 (e) and dose 2 (g) (ID50 > 1 in 20 dilution of sera). GMT ± s.d. are representative of two independent experiments each with two technical repeats. Mann–Whitney test was used for unpaired comparisons and Wilcoxon matched-pairs signed rank test for paired comparisons. *P < 0.05, **P < 0.01, ****P < 0.0001; NS, not significant. HS, human AB serum control.